Chondrosarcoma clinical trials

Explore recruiting chondrosarcoma clinical trials.

Recruiting chondrosarcoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Chondrosarcoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Blinded, Placebo-Controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

France, Italy, Germany, Ireland, Netherlands, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ≥18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 or 2 systemic treatment regimens (CHONQUER study)

Germany, Italy, France, Spain, Netherlands, Belgium +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase II study on trabectedin in adults and young adults HEY1-NOCA2 positive skeletal and extra-skeletal mesenchymal chondrosarcoma (MCS)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1 Study of HMPL-306 in Locally Advanced Solid Tumors with IDH mutations

Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

REGOBONE_A Randomized Phase II, placebo-controlled, multicenter study evaluating efficacy and safety of regorafenib in patients with metastatic bone sarcomas

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1 Study on the effects of LY3410738 (study drug) administered to Patients with Advanced Solid Tumors with IDH1 or IDH2 Mutations

France, Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Chondrosarcoma trials by city

Chondrosarcoma in Toronto Chondrosarcoma in Vancouver Chondrosarcoma in Montreal Chondrosarcoma in Calgary Chondrosarcoma in Edmonton Chondrosarcoma in Ottawa Chondrosarcoma in Winnipeg Chondrosarcoma in Quebec City Chondrosarcoma in Hamilton Chondrosarcoma in Kitchener Chondrosarcoma in London Chondrosarcoma in Halifax Chondrosarcoma in New York Chondrosarcoma in Los Angeles Chondrosarcoma in Chicago Chondrosarcoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease